Our venture capital fund focuses investments on early-stage life sciences companies looking to improve people’s outcomes with cancer.

Recent News

wugen-logo-400
06/29/2021

Cell-based immunotherapy shows promise against melanoma

READ MORE
C4-logo-400
06/21/2021

C4 Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

READ MORE
C4-logo-400
06/21/2021

C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the 16th Annual International Conference on Malignant Lymphoma

READ MORE
C4-logo-400
06/16/2021

C4 Therapeutics Announces Pricing of Public Offering

READ MORE
C4-logo-400
06/14/2021

C4 Therapeutics Launches Proposed Public Offering

READ MORE
C4-logo-400
06/14/2021

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable MonoDAC for Hematologic Malignancies

READ MORE
CareVet-Logo-New
06/08/2021

CareVet Launches Comprehensive Learning Institute

READ MORE
C4-logo-400
06/07/2021

C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L858R, at Keystone Symposium on Targeted Protein Degradation

READ MORE
C4-logo-400
05/26/2021

C4 Therapeutics to Advance CFT8919, A Selective Degrader of EGFR L858R, Into IND-enabling Studies

READ MORE

PORTFOLIO HIGHLIGHTS

WUGEN Logo
White C4 Therapeutics logo
Geneoscopy logo
NextRNA Logo
CareVet Logo
microbial-logo-header300